Theseus Pharmaceuticals (THRX) IPO Opens 30% Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Theseus Pharmaceuticals (THRX) Prices 10M Share IPO at $16/sh
October 7, 2021 5:40 AM EDTTheseus Pharmaceuticals, Inc. (NASDAQ: THRX), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced the pricing of its initial public offering of 10,000,200 shares of its common stock at a price to the public of $16.00 per share. All of the shares are being offered by Theseus. The gross proceeds to Theseus from the offering, before deducting underwriting discounts, commissions and other offering expenses payable by Theseus, are expected to be $160 million. In addition, Theseus has... More
